A significant secretion of the anti-tumor-associated cytokines (e.g., TNF-α) was also observed in the serum of patients four hours after intravenous administration, which could partially explain the anti-tumor effect of the engineered OMVs 86. This evidence concerns the gene TNF and neoplasm.